Molecular Biomarkers in Peptic Ulcer Disease: Bridging Pathophysiology and Personalized Management

I. Introduction: The Evolving Landscape of Peptic Ulcer Disease

A. Brief Overview of Peptic Ulcer Disease (PUD)

Peptic Ulcer Disease (PUD) is a prevalent gastrointestinal disorder defined by a mucosal discontinuity, characterized by breaks that extend through the entire thickness of the mucosa, penetrating into the submucosa or deeper layers of the stomach or duodenum.¹ Pathophysiologically, PUD results from a critical breakdown in the delicate balance between aggressive factors (primarily hydrochloric acid and pepsin) and the stomach’s robust mucosal protective factors (mucus, bicarbonate, and adequate blood flow).²

B. Global Prevalence and Clinical Importance

PUD remains a significant burden on global healthcare, although its etiology and prognosis have undergone notable transformations in recent decades. Analysis of global epidemiological data reveals that the overall case burden continues to rise. The worldwide incidence of PUD increased, with cases reaching 2,854,370 in 2021, representing an 11.05% cumulative growth since 1990.⁴ Concurrently, global prevalence cases reached 6,567,782 in 2021, marking an 8.77% cumulative growth over the same period.⁴ Incidence and prevalence rates remain consistently higher in males, though the age-standardized mortality rate (ASMR) has been noted to be higher in women.⁴ Critically, while the number of PUD cases has grown, the global age-standardized mortality rate (ASMR) has decreased dramatically, falling from 7.14 per 100,000 population in 1990 to 2.75 per 100,000 in 2021.⁴ This decoupling suggests that while acute treatment and management of severe complications (like bleeding or perforation) have improved significantly, the underlying factors initiating ulcer formation remain inadequately controlled, driving the overall rise in incidence. This shift in the clinical challenge—from managing high mortality to mitigating rising case numbers—points directly to the changing dominant etiologies, particularly the increasing reliance on nonsteroidal anti-inflammatory drugs (NSAIDs) among the aging global population, requiring diagnostic tools (biomarkers) capable of identifying non-infectious damage.

C. Role of Biomarkers in Understanding Disease Mechanisms and Management

Biomarkers—measurable indicators of a biological state—are indispensable in modern clinical practice, offering a non-invasive window into disease progression and response to therapy. In PUD, they provide essential capabilities for early non-invasive diagnosis, identifying individuals at high risk for complications or recurrence, and tailoring specific therapies based on molecular profiles.⁶ The evaluation of biomarkers moves diagnosis beyond simple symptom reporting or expensive endoscopy, enabling precision medicine approaches that optimize clinical outcomes.⁶

D. Purpose and Scope of the Review

This expert review systematically evaluates the established, emerging, and future molecular biomarkers relevant to PUD. The scope encompasses markers of inflammation, oxidative stress, mucosal integrity, infection status, and genetic predisposition, assessed for their roles in diagnosis, prognosis, and personalized therapeutic prediction.

II. Pathophysiology of Peptic Ulcer Disease: Mechanistic Detail

A. Mechanisms of Mucosal Injury: The Homeostatic Balance

The integrity of the gastric mucosa is maintained by a complex, multi-layered defensive barrier involving pre-epithelial mucus and bicarbonate secretion, epithelial cell function (rapid turnover and tight junctions), and sub-epithelial blood flow regulated by local mediators. PUD develops when aggressive factors overcome these defenses. Historically, the two primary drivers of PUD are infection with Helicobacter pylori and the use of NSAIDs.²

B. Role of Helicobacter pylori Infection

H. pylori infection facilitates mucosal injury through several mechanisms, including the direct action of cytotoxins (such as VacA and CagA) and the induction of chronic, deep-seated inflammation. The resulting gastritis weakens the mucosal barrier, compromises epithelial integrity, and often leads to mucosal atrophy, making the lining vulnerable to acid and pepsin.²

C. NSAID-Induced Ulcers: The Dual Pathogenicity Model

The clinical significance of NSAID-induced PUD has grown substantially, particularly with the aging population, and the mechanisms involved are distinct and profound. NSAID damage operates via two critical pathways ²:

1. Systemic Mechanism (COX-1 Inhibition):

 NSAIDs inhibit cyclooxygenase (COX) enzymes. The primary pathogenic mechanism involves the inhibition of the constitutively expressed COX-1 enzyme. This blockage dramatically reduces the synthesis of protective prostaglandins, which are essential for maintaining mucosal integrity. The decrease in prostaglandins leads to three critical defects: diminished mucus and bicarbonate secretion, impaired cell proliferation, and a reduction in mucosal blood flow. The resulting systemic compromise fundamentally weakens the entire defensive apparatus.

2. Direct Mucosal Injury (Topical/Cellular Mechanism):

 Separate from COX inhibition, NSAIDs also cause direct, topical damage to the gastric epithelium. As weak acids, they disrupt mucus phospholipids and cell membranes, initiating cellular damage. A highly specific consequence of this process is the uncoupling of mitochondrial oxidative phosphorylation within the epithelial cells.³ This mechanism is crucial because it immediately generates reactive oxygen species (ROS), providing a direct mechanistic link to the biomarkers discussed in Section 4.2.

D. Imbalance and Synergistic Interactions

The rising prevalence of NSAID use, especially among the elderly population being treated for chronic conditions, has resulted in a considerable healthcare burden.³ Retrospective studies have clearly demonstrated this risk: elderly NSAID users experience a substantially higher ulcer hospitalization rate (16.7 per 1,000 person-years) compared to nonusers (4.2 per 1,000 person-years).³ Furthermore, the simultaneous presence of H. pylori and chronic NSAID use exhibits a powerful synergistic effect. H. pylori weakens the mucosa through chronic inflammation, while NSAIDs compromise protection through prostaglandin depletion and direct cellular injury. Patients with both risk factors face a 3.53-fold higher risk of peptic ulcers and associated complications, such as bleeding, compared to those with either factor alone.³ It is essential to recognize that even after successful H. pylori eradication, chronic NSAID users remain at high risk of ulcer recurrence due to persistent prostaglandin depletion and impaired mucosal integrity.³ This necessitates a diagnostic strategy that can monitor for the molecular damage inflicted by NSAIDs independently of the infection status, making non-infectious biomarkers critical for ongoing management.